Vermont Medicaid and semaglutide
Wegovy for weight loss: no. Criteria cover heart risk reduction with a BMI over 27 and a listed event, and MASH with fibrosis (injection only), in members without diabetes. Ozempic for weight loss: no; for type 2 diabetes Vermont Medicaid must cover it. Read from Department of Vermont Health Access documents Nov 6, 2026.
In 2025 Vermont Medicaid paid for 8,393 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 49% of its GLP-1 prescriptions and 46th of the 50 states and DC. It reimbursed $9.4 million before rebates, $1,123 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 7,813 | $8.8 million | $1,121 |
| Rybelsus | 439 | $542,893 | $1,237 |
| Wegovy | 141 | $122,550 | $869 |
Semaglutide in the states around Vermont
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Vermont | 19 | $39/moWellmedr | 8,393 | Medicaid Wegovy: No |
| Massachusetts | 18 | $39/moWellmedr | 53,347 | Medicaid Wegovy: No |
| New Hampshire | 19 | $39/moWellmedr | 21,492 | Medicaid Wegovy: No |
| New York | 19 | $39/moWellmedr | 488,820 | Medicaid Wegovy: No |



